STVN:NYSEStevanato Group S.p.A. Analysis
Data as of 2026-09-12 - not real-time
$20.90
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Stevanato Group S.p.A. trades at $20.90, with its short-term moving averages stacked above the longer-term ones — a bullish trend structure. It has gained 3.5% over the past 30 days. RSI sits at 50.2, which reads as neutral, and MACD momentum is bearish. Recent trading has carved out support near $19.74 and resistance around $23.18.
The shares look fair, trading on 36.7 times earnings above a sector average of 29.5. The average analyst target implies 18.8% above today's level. Revenue is growing at 7.8% on a 11.0% profit margin. The 0.29% dividend yield looks covered by current payout levels.
On a 1-10 scale the risk profile lands at 8 — high. With 30-day volatility of 35.6%, a beta of 1.17 and a maximum drawdown of 51.4%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
The horizons line up on hold — conviction 1 out of 10.
The shares look fair, trading on 36.7 times earnings above a sector average of 29.5. The average analyst target implies 18.8% above today's level. Revenue is growing at 7.8% on a 11.0% profit margin. The 0.29% dividend yield looks covered by current payout levels.
On a 1-10 scale the risk profile lands at 8 — high. With 30-day volatility of 35.6%, a beta of 1.17 and a maximum drawdown of 51.4%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
The horizons line up on hold — conviction 1 out of 10.
Top Market Events
Stevanato Group SpA STVN reports 8% revenue growth, 280 bps EBITDA margin expansion, and a key European regulatory...What Stevanato Group’s latest earnings and guidance mean for investors Stevanato Group STVN has been in focus after...The regulatory approvals cover therapies for diabetes and weight management, further expanding the commercial adoption...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 2/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 18.31
- MACD momentum is negative
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked above long-term ones
- P/E of 36.7 versus sector average of 29.5
- Trading above the 200-day average of 18.31
Long Term
> 3 yearsNeutral
Model confidence: 1/10
Key Factors
- P/E of 36.7 versus sector average of 29.5
- Analyst targets imply +18.8% versus the current price
- Negative free cash flow
Key Metrics & Analysis
Financial Health
Revenue Growth7.80%
Profit Margin10.99%
P/E Ratio36.7
ROE9.13%
ROA5.45%
Debt/Equity28.73
P/B Ratio3.2
Op. Cash Flow$248.7M
Free Cash Flow$-104701248
Industry P/E29.5
Technical Analysis
TrendBullish
RSI50.2
Support$19.74
Resistance$23.18
MA 20$21.36
MA 50$20.48
MA 200$18.31
MACDBearish
VolumeDecreasing
Fear & Greed Index93.14
Valuation
Fair Value$9.61
Target Price$24.83
Upside/Downside18.79%
GradeFair
TypeGrowth
Dividend Yield0.29%
Risk Assessment
Beta1.17
Volatility35.64%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.